Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“IFN-ɤ, an important cytokine involved in antitumor immunity, could upregulate MHC expression on tumor cells and M1 macrophages and facilitate the recognition and elimination of transformed cells (91, 92).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…for macrophages that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs…”
BackgroundTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Using the 3 methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system in WT mice could edit tumors more effectively than the immune system in RAG2 / mice (which lack adaptive immunity; Shankaran et al., 2001; Takahashi and Yamanaka, 2006), but we did not assess whether tumors from RA…”
MethodCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 4×
“M1 macrophages are activated classically via IFN- and function in the removal of intracellular pathogens (Gordon and Taylor, 2005).”
BackgroundResultInfluentialThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 13×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodResultInfluentialSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“…characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al.,…”
MethodDistinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · cited 2×
“…that these macrophages were classically activated (Gordon and Taylor, 2005) M1 macrophages and performed immunophenotyping to detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008).”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150 · cited 1×
“Genotyping was performed using PCR (for IL-2R c, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern blot for RAG2 (Shinkai et al., 1992).”
Method
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
“Moreover, CX3CR-1 patrolling monocytes inhibit metastatic progression through the recruitment of NK cells to the metastatic site, and then NK cell-derived IFN-γ reprograms macrophages into a tumoricidal effector macrophage state (O’Sullivan et al. 2012).”
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Self-citationRole of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01124 · Cited by 825
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
Malladi, S., Macalinao, D. G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., & Massagué, J. (2016) · Cell · doi:10.1016/j.cell.2016.02.025 · Cited by 791
Control of Metastasis by NK Cells
López-Soto, A., Gonzalez, S., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 736
Self-citationTargeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 625
Alspach, E., Lussier, D. M., & Schreiber, R. D. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028480 · Cited by 603
Self-citationThe hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
Tumor-associated macrophages: Functional diversity, clinical significance, and open questions
Biswas, S. K., Allavena, P., & Mantovani, A. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0367-7 · Cited by 551
“In this regard, a recent study showed that in absence of adaptive immune cells, NK cell-derived IFNγ could drive TAMs to an M1 state which could be an effector for cancer immunoediting [128] (Fig.”
BackgroundAcquired resistance to immunotherapy and future challenges
Restifo, N. P., Smyth, M. J., & Snyder, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.2 · Cited by 467
Self-citationCellular backpacks for macrophage immunotherapy
Shields, C. W., Evans, M. A., Wang, L. L.-W., Baugh, N., Iyer, S., Wu, D., Zhao, Z., Pusuluri, A., Ukidve, A., Pan, D. C., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz6579 · Cited by 414
Recognition of Tumors by the Innate Immune System and Natural Killer Cells
Marcus, A., Gowen, B. G., Thompson, T. W., Iannello, A., Ardolino, M., Deng, W., Wang, L., Shifrin, N., & Raulet, D. H. (2014) · Advances in Immunology · doi:10.1016/b978-0-12-800267-4.00003-1 · Cited by 394
“Although cooperation between different leukocytes has not been deeply explored in the context of tumor immunology, a recent report suggested that NK-cell-derived IFN-g polarizes macrophages toward a tumoricidal “M1” state that confers protection from carcinogen-induced sarcomas (O’Sullivan et al., 2012).”
A Breakthrough: Macrophage-Directed Cancer Immunotherapy
Mills, C. D., Lenz, L. L., & Harris, R. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1737 · Cited by 356
“The tumor environment or the lack of activating stimuli also seems to play a role in limiting the activation of other innate responses, such as natural killer cells that can kill tumor cells directly, or augment M1/kill-type activation through IFNg production (20).”
Mouse models in oncoimmunology
Zitvogel, L., Pitt, J. M., Daillère, R., Smyth, M. J., & Kroemer, G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.91 · Cited by 343
Self-citationImmunosuppressive mechanisms in glioblastoma: Fig. 1.
Nduom, E. K., Weller, M., & Heimberger, A. B. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov151 · Cited by 348
Oncolytic virus immunotherapy: future prospects for oncology
Raja, J., Ludwig, J. M., Gettinger, S. N., Schalper, K. A., & Kim, H. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0458-z · Cited by 313
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Efremova, M., Rieder, D., Klepsch, V., Charoentong, P., Finotello, F., Hackl, H., Hermann-Kleiter, N., Löwer, M., Baier, G., Krogsdam, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02424-0 · Cited by 297
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Bos, P. D., Plitas, G., Rudra, D., Lee, S. Y., & Rudensky, A. Y. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130762 · Cited by 296
Adipose-resident group 1 innate lymphoid cells promote obesity-associated insulin resistance
O’Sullivan, T. E., Rapp, M., Fan, X., Weizman, O.-E., Bhardwaj, P., Adams, N. M., Walzer, T., Dannenberg, A. J., & Sun, J. C. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.016 · Cited by 293
“Although mature NK cells play a critical role in response to viral infection and transformed cells (O’Sullivan et al., 2012; Sun and Lanier, 2011), much less is known about the importance of other tissue-resident group 1 ILCs in immune protection or pathology.”
BackgroundSelf-citationMantovani, A., & Locati, M. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.300168 · Cited by 290
Zheng, X., Turkowski, K., Mora, J., Brüne, B., Seeger, W., Weigert, A., & Savai, R. (2017) · Oncotarget · doi:10.18632/oncotarget.17061 · Cited by 277
TNF Counterbalances the Emergence of M2 Tumor Macrophages
Kratochvill, F., Neale, G., Haverkamp, J. M., Van de Velde, L.-A., Smith, A. M., Kawauchi, D., McEvoy, J., Roussel, M. F., Dyer, M. A., Qualls, J. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.033 · Cited by 277
“We built upon methodologies (Movahedi et al., 2010; O'Sullivan et al., 2012) where the CD11b+ fraction was sub-divided into four populations: neutrophils (Ly6G+, CD11b+), the TAMs directly descended from blood monocytes called TAM-A (CD11b+, Ly6Chi, MHCII−), TAM-B (CD11b+, Ly6C+, MHCII+) and TAM-C…”
Asrir, A., Tardiveau, C., Coudert, J., Laffont, R., Blanchard, L., Bellard, E., Veerman, K., Bettini, S., Lafouresse, F., Vina, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.002 · Cited by 257
Chen, S., Zhu, H., & Jounaidi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02005-w · Cited by 234
“404 Depending on the infectious agent, NK cells will express speci fi c receptors to speci fi c ligands, the involved macrophages express.”
BackgroundTargeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
Ward, J. P., Gubin, M. M., & Schreiber, R. D. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2016.01.001 · Cited by 228
Self-citationRelevance of tumor-infiltrating lymphocytes in breast cancer
Dushyanthen, S., Beavis, P. A., Savas, P., Teo, Z. L., Zhou, C., Mansour, M., Darcy, P. K., & Loi, S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0431-3 · Cited by 227
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
Marty Pyke, R., Thompson, W. K., Salem, R. M., Font-Burgada, J., Zanetti, M., & Carter, H. (2018) · Cell · doi:10.1016/j.cell.2018.08.048 · Cited by 211
Monocytes and Macrophages in Cancer: Development and Functions
Richards, D. M., Hettinger, J., & Feuerer, M. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0123-x · Cited by 210
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200
Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells
Wang, B., Wang, Q., Wang, Z., Jiang, J., Yu, S.-C., Ping, Y.-F., Yang, J., Xu, S.-L., Ye, X.-Z., Xu, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2563 · Cited by 198
M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
Zong, Z., Zou, J., Mao, R., Ma, C., Li, N., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01643 · Cited by 196
Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
Medrano, R. F. V., Hunger, A., Mendonça, S. A., Barbuto, J. A. M., & Strauss, B. E. (2017) · Oncotarget · doi:10.18632/oncotarget.19531 · Cited by 182
NK cells are never alone: crosstalk and communication in tumour microenvironments
Zhou, Y., Cheng, L., Liu, L., & Li, X. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01737-7 · Cited by 172
A toll-like receptor agonist mimicking microbial signal to generate tumor-suppressive macrophages
Feng, Y., Mu, R., Wang, Z., Xing, P., Zhang, J., Dong, L., & Wang, C. (2019) · Nature Communications · doi:10.1038/s41467-019-10354-2 · Cited by 170
Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase
Gong, L., Cumpian, A. M., Caetano, M. S., Ochoa, C. E., De la Garza, M. M., Lapid, D. J., Mirabolfathinejad, S. G., Dickey, B. F., Zhou, Q., & Moghaddam, S. J. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-154 · Cited by 150
“Low iNOS and high arginase 1 expressions are two other important indicators of N2 type neutrophils [20-22].”
Iron induces anti-tumor activity in tumor-associated macrophages
Costa da Silva, M., Breckwoldt, M. O., Vinchi, F., Correia, M. P., Stojanovic, A., Thielmann, C. M., Meister, M., Muley, T., Warth, A., Platten, M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01479 · Cited by 164
Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation
Singh, M., Khong, H., Dai, Z., Huang, X.-F., Wargo, J. A., Cooper, Z. A., Vasilakos, J. P., Hwu, P., & Overwijk, W. W. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401160 · Cited by 166
Davis, R. J., Van Waes, C., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 163
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression
Awad, R. M., De Vlaeminck, Y., Maebe, J., Goyvaerts, C., & Breckpot, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01977 · Cited by 151
Morris, Z. S., Guy, E. I., Francis, D. M., Gressett, M. M., Werner, L. R., Carmichael, L. L., Yang, R. K., Armstrong, E. A., Huang, S., Navid, F., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2644 · Cited by 160
“Multiple studies of clinically relevant murine tumor models indicate that the most immunogenic tumor antigens recognized by T cells are "private antigens" derived frommutated proteins in tumor cells (14, 15).”
NK Cells in the Tumor Microenvironment
Guillerey, C. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_4 · Cited by 174
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
von Locquenghien, M., Rozalén, C., & Celià-Terrassa, T. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143296 · Cited by 149
Balancing the innate immune system in tumor development
Hagerling, C., Casbon, A.-J., & Werb, Z. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.001 · Cited by 133
“NK cells reprogram macrophages into becoming tumoricidal through the production of IFN-γ, and the overexpression of miR-155 in TAMs repolarizes them into a tumoricidal M1 phenotype[45, 46].”
Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance
Saddawi-Konefka, R., Seelige, R., Gross, E. T. E., Levy, E., Searles, S. C., Washington, A., Santosa, E. K., Liu, B., O’Sullivan, T. E., Harismendy, O., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.075 · Cited by 126
“Tumorigenesis and Tumor Transplantations Primary tumorigenesis was performed as previously described (O’Sullivan et al., 2012; Shankaran et al., 2001).”
InfluentialSelf-citationInterstitial flow promotes macrophage polarization toward an M2 phenotype
Li, R., Serrano, J. C., Xing, H., Lee, T. A., Azizgolshani, H., Zaman, M., & Kamm, R. D. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-03-0164 · Cited by 125
Immunobiology of cholangiocarcinoma
Loeuillard, E. J., Conboy, C. B., Gores, G. J., & Ilyas, S. I. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.003 · Cited by 131
“NK cells also play an essential role in cancer immunoediting via secretion of interferon-gamma which induces activation of M1-like macrophages.(50) Nonetheless, it has been postulated that the predominant role of NK cells in tumour immunosurveillance might be prevention of metastasis, as NK cells are abundant in the c…”
Bristow, R. G., Alexander, B. M., Baumann, M. A., Bratman, S. V., Brown, J. M., Camphausen, K. A., Choyke, P. L., Citrin, D. E., Contessa, J. N., Dicker, A. P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30096-2 · Cited by 128
Targeting Innate Immunity in Cancer Therapy
Rameshbabu, S., Labadie, B. W., Argulian, A., & Patnaik, A. (2021) · Vaccines · doi:10.3390/vaccines9020138 · Cited by 129
CXCR3 enables recruitment and site-specific bystander activation of memory CD8(+) T cells
Maurice, N. J., McElrath, M. J., Andersen-Nissen, E., Frahm, N., & Prlic, M. (2019) · Nature Communications · doi:10.1038/s41467-019-12980-2 · Cited by 117
Mathematical and Computational Modeling in Complex Biological Systems
Ji, Z., Yan, K., Li, W., Hu, H., & Zhu, X. (2017) · BioMed Research International · doi:10.1155/2017/5958321 · Cited by 129
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Swamydas, M., Murphy, E. V., Ignatz-Hoover, J. J., Malek, E., & Driscoll, J. J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01234-2 · Cited by 133
Ruf, B., Greten, T. F., & Korangy, F. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00562-w · Cited by 121
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
Shui, L., Yang, X., Li, J., Yi, C., Sun, Q., & Zhu, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02989 · Cited by 115
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
Poli, A., Wang, J., Domingues, O., Planagumà, J., Yan, T., Rygh, C. B., Skaftnesmo, K. O., Thorsen, F., McCormack, E., Hentges, F., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1291 · Cited by 115
“Moreover, the immunomodulation capacity of NK cells through cytokine secretion could skew tumorassociated macrophages (TAM) from anti-inflammatory to pro-inflammatory phenotypes [22] and was shown to enhance tumor immunoediting [23].”
CD40 immunotherapy for pancreatic cancer
Vonderheide, R. H., Bajor, D. L., Winograd, R., Evans, R. A., Bayne, L. J., & Beatty, G. L. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1427-5 · Cited by 114
Bioactive Nanoparticles for Cancer Immunotherapy
Surendran, S. P., Moon, M. J., Park, R., & Jeong, Y. Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123877 · Cited by 116
The Immune Microenvironment of Breast Cancer Progression
Tower, H., Ruppert, M., & Britt, K. L. (2019) · Cancers · doi:10.3390/cancers11091375 · Cited by 132
The footprint of kynurenine pathway in every cancer: a new target for chemotherapy
Ala, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173921 · Cited by 112
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Chulpanova, D. S., Kitaeva, K. V., Green, A. R., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00402 · Cited by 114
Loong, J. H. C., Wong, T. L., Tong, M., Sharma, R., Zhou, L., Ng, K. Y., Yu, H.-J., Li, C.-H., Man, K., Lo, C. M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143377 · Cited by 105
Xia, X., Mai, J., Xu, R., Perez, J. E. T., Guevara, M. L., Shen, Q., Mu, C., Tung, H.-Y., Corry, D. B., Evans, S. E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.009 · Cited by 103
“Previous reports also identified anti-tumor immunity accompanied by increased intra-tumoral MHCII expression after treatment with the agonist anti-CD40 antibody, which was attributed to activated innate immune cells (mainly macrophages) (Beatty et al., 2011; O’Sullivan et al., 2012).”
Pahl, J. H., Kwappenberg, K. M., Varypataki, E. M., Santos, S. J., Kuijjer, M. L., Mohamed, S., Wijnen, J. T., van Tol, M. J., Cleton-Jansen, A.-M., Egeler, R. M., et al. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-27 · Cited by 101
Brackett, C. M., Kojouharov, B., Veith, J. M., Greene, K. F., Burdelya, L. G., Gollnick, S. O., Abrams, S. I., & Gudkov, A. V. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521359113 · Cited by 107
Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer
Shah, Z., Tian, L., Li, Z., Jin, L., Zhang, J., Li, Z., Barr, T., Tang, H., Feng, M., Caligiuri, M. A., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.03.018 · Cited by 117
NK Cells and Cancer Immunoediting
Guillerey, C., & Smyth, M. J. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_446 · Cited by 111
Self-citationA temporal perspective for tumor-associated macrophage identities and functions
Blériot, C., Dunsmore, G., Alonso‐Curbelo, D., & Ginhoux, F. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.002 · Cited by 111
Guerra, A. D., Yeung, O. W. H., Qi, X., Kao, W. J., & Man, K. (2017) · Theranostics · doi:10.7150/thno.20251 · Cited by 92
Inflammasome-Dependent Induction of Adaptive NK Cell Memory
van den Boorn, J. G., Jakobs, C., Hagen, C., Renn, M., Luiten, R. M., Melief, C. J. M., Tüting, T., Garbi, N., Hartmann, G., & Hornung, V. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.008 · Cited by 96
“On the other hand, Rag2 / mice that received an NK cell-sensitive non-pigmented methylcholanthrene (MCA)-induced sarcoma (O’Sullivan et al., 2012) following monobenzone-sensitization, did not repress the outgrowth of this tumor (Figure 2F).”
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk
Piening, A., Ebert, E. C., Gottlieb, C., Khojandi, N., Kuehm, L. M., Hoft, S. G., Pyles, K. D., McCommis, K. S., DiPaolo, R. J., Ferris, S. T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47359-5 · Cited by 118
“Increased cancer risk in immunocompromised individuals and animal models have provided clear evidence that immune surveillance is critical for detecting and eliminating potentially malignant cells throughout the body and for opposing tumor progression 33 – 38 .”
DuPage, M., & Jacks, T. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.005 · Cited by 91
Muntasell, A., Cabo, M., Servitja, S., Tusquets, I., Martinez‐García, M., Rovira, A., Rojo, F., Albanell, J., & López‐Botet, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01544 · Cited by 97
Interleukin-17D Mediates Tumor Rejection through Recruitment of Natural Killer Cells
O’Sullivan, T., Saddawi-Konefka, R., Gross, E., Tran, M., Mayfield, S. P., Ikeda, H., & Bui, J. D. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.073 · Cited by 88
Self-citationImmune Evasion by Head and Neck Cancer: Foundations for Combination Therapy
Horton, J. D., Knochelmann, H. M., Day, T. A., Paulos, C. M., & Neskey, D. M. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.02.007 · Cited by 103
Advantages and clinical applications of natural killer cells in cancer immunotherapy
Ames, E., & Murphy, W. J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1469-8 · Cited by 100
“In hematological malignancies, immunoediting occurs between the malignant cells and NK cells allowing clones of tumor cells to grow out which are no longer recognized by NK cells [51, 52].”
BackgroundShaping of NK Cell Responses by the Tumor Microenvironment
Stojanovic, A., Correia, M. P., & Cerwenka, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0125-8 · Cited by 105
Zhang, W., Liu, H., Liu, W., Liu, Y., & Xu, J. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.142 · Cited by 86
Zhang, X., Ashcraft, K. A., Warner, A. B., Nair, S. K., & Dewhirst, M. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2468 · Cited by 95
“Tumor-associated macrophages (TAM) also contribute to innate antitumor immunity (43).”
Sun, J. T., Sun, J., Song, B., Zhang, L., Shao, Q., Liu, Y., Yuan, D., Zhang, Y., & Qu, X. (2016) · Scientific Reports · doi:10.1038/srep35855 · Cited by 95
Mechanisms and Αpplications of Ιnterleukins in Cancer Immunotherapy
Anestakis, D., Petanidis, S., Kalyvas, S., Nday, C., Tsave, O., Kioseoglou, E., & Salifoglou, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16011691 · Cited by 79
Mori, K., Haraguchi, S., Hiori, M., Shimada, J., & Ohmori, Y. (2015) · BMC Cancer · doi:10.1186/s12885-015-1587-0 · Cited by 80
Circulating CD56bright NK cells inversely correlate with survival of melanoma patients
de Jonge, K., Ebering, A., Nassiri, S., Hajjami, H. M.-E., Ouertatani-Sakouhi, H., Baumgaertner, P., & Speiser, D. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40933-8 · Cited by 82
Gaggero, S., Witt, K., Carlsten, M., & Mitra, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.621225 · Cited by 85
Innate immune evasion revealed in a colorectal zebrafish xenograft model
Póvoa, V., de Almeida, C. R., Maia-Gil, M., Sobral, D., Domingues, M., Martínez-López, M. F., Fuzeta, M. D. A., Silva, C., Grosso, A. R., & Fior, R. (2021) · Nature Communications · doi:10.1038/s41467-021-21421-y · Cited by 75
Arrested development: suppression of NK cell function in the tumor microenvironment
Riggan, L., Shah, S. N., & O’Sullivan, T. E. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1238 · Cited by 81
Self-citationKubo, H., Mensurado, S., Gonçalves‐Sousa, N., Serre, K., & Silva‐Santos, B. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0082 · Cited by 78
Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer
Knocke, S., Fleischmann-Mundt, B., Saborowski, M., Manns, M. P., Kühnel, F., Wirth, T. C., & Woller, N. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.086 · Cited by 75
Jaiswal, A. R., Liu, A. J., Pudakalakatti, S., Dutta, P., Jayaprakash, P., Bartkowiak, T., Ager, C. R., Wang, Z., Reuben, A., Cooper, Z. A., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0005 · Cited by 74
Allen, C. T., Clavijo, P. E., Waes, C. V., & Chen, Z. (2015) · Cancers · doi:10.3390/cancers7040900 · Cited by 73
Hernández, Á., Juanes‐Velasco, P., Landeira‐Viñuela, A., Bareke, H., Montalvillo, E., Góngora, R., & Fuentes, M. (2021) · Cancers · doi:10.3390/cancers13112821 · Cited by 76
TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?
Meulenaere, A. D., Vermassen, T., Aspeslagh, S., Vandecasteele, K., Rottey, S., & Ferdinande, L. (2016) · Head and Neck Pathology · doi:10.1007/s12105-016-0776-8 · Cited by 71
Cancer Immunosurveillance and Immunoediting by Natural Killer Cells
Gross, E., Sunwoo, J. B., & Bui, J. D. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000005 · Cited by 64
Self-citationMolecular mechanisms of immunotherapy resistance in triple-negative breast cancer
Zheng, Y., Li, S., Tang, H., Meng, X., & Zheng, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1153990 · Cited by 79
Roehle, K., Li, Q., Ventre, K. S., Heid, D., Ali, L. R., Lenehan, P. J., Heckler, M., Crowley, S. J., Stump, C. T., Ro, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5058 · Cited by 64
Ardighieri, L., Missale, F., Bugatti, M., Gatta, L. B., Pezzali, I., Monti, M., Gottardi, S., Zanotti, L., Bignotti, E., Ravaggi, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690201 · Cited by 69
“M1 M f initiates pro-in fl ammatory responses and promotes direct or T-cell mediated antitumor effector functions (34, 36) particularly in highly immunogenic cancer (35).”
Self-citationChallenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors
Lian, G., Mak, T. S., Yu, X., & Lan, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010164 · Cited by 72
Mechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 70
Metadata
- Authors
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
- Affiliations
- University of California San Diego (US)
- Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Center for Immunology, Department of Pathology and Immunology 3 and 4
- The University of Melbourne (AU)
- Corresponding author
- Bui, Jack D.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-08-27
- Volume
- 209
- Issue
- 10
- Pages
- 1869-1882
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3457735
- OpenAlex
- W2144577255
- Cited by
- 348
- References
- 58
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Cancer Research Institute
- Concern Foundation
- Hartwell Foundation (CA157885)
- Ludwig Institute for Cancer Research
- Cancer Research Coordinating Committee
- National Institutes of Health (CA157885)
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
- National Center for Research Resources (C06RR012466)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.